Giorgis Isaac

Giorgis Isaac

Waters Corporation, USA

Title: Targeted and untargeted lipidomics reveal unique lipid profile in


Giorgis Isaac is a Principal Scientist, Pharmaceutical Business Operations at Waters Corporation, USA. Development of global profiling and targeted methodologies for lipid and metabolite identification using different analytical tools. He completed his Post Doc in 2010 at Pacific Northwest National Laboratory.


Essential fats, such as omega-3 and omega-6 fatty acids, must be obtained through the diet and cannot be synthesized de novo in mammals. In 2004, the fat-1 transgenic mouse model was developed, enabling the mouse to endogenously convert omega-6 to omega-3 fatty acids. Research has demonstrated that the fat-1 mouse is protected against a wide variety of diseases and conditions related to inflammation including colitis, pancreatitis, asthma, hepatitis, liver disease, atherosclerosis, insulin resistance, and several types of cancer (breast, colon, pancreatic, liver). Although a large number of studies have demonstrated reduced disease risk and health benefits in fat-1 mice, a comprehensive comparison of lipids profiles in fat-1 and wild-type mice has not been previously feasible due to lack of a sensitive and comprehensive analytical technique capable of simultaneously quantifying high-abundance (e.g., phospholipids) and low abundance lipids (e.g., oxylipins). In this study, we used a state-of-the-art, high-throughput assays for the analysis of bioactive lipid species in plasma and liver samples from fat-1 and wild-type mice, providing new clues to the pathways and mechanisms that may be involved in health benefits associated with alterations of the omega-6/omega-3 fatty acids ratio.

Speaker Presentations

Speaker PDFs